心房颤动患者近期缺血性卒中后应用依多沙班抗凝治疗的时机和剂量的研究进展

心房颤动（Atrial fibrillation,AF）是成人中常见的持续性心律失常，给医疗保健增加巨大负担。心律失常不仅与生活质量下降和频繁住院有关，而且与缺血性卒中、其他血栓栓塞事件和死亡率增加的风险增加有关。AF患者的缺血性卒中风险因个体风险状况而异，不使用口服抗凝剂（Oral anticoagulant,OAC）的缺血性卒中发生率约为3.20/100人年。与其他卒中病因相比，AF相关卒中患者的预后更差。所有AF患者都必须实施个体卒中风险评估和使用最佳卒中预防策略。依多沙班的适应证是预防AF患者的卒中，该药口服给药，剂量为60 mg，每日1次。本文讨论了AF患者近期缺血性卒中后应用依多沙班抗凝治疗的时机和剂量的研究进展。

Research progress on the timing and dose of edoxaban anticoagulant therapy in patients with atrial fibrillation after recent ischemic stroke

Atrial fibrillation(AF)is the most common persistent arrhythmia in adults and poses a huge burden for healthcare.Arrhythmias are associated not only with reduced quality of life and frequent hospitalizations,but also with an increased risk of ischemic stroke,other thromboembolic events,and increased mortality.The risk of ischemic stroke in AF patients varies with individual risk status,and the incidence of ischemic stroke without Oral anticoagulant(OAC)is approximately 3.20/100 person-years.AF-related stroke has a worse prognosis than other stroke causes.All patients with AF must undergo an individual stroke risk assessment and use optimal stroke prevention strategies.Edoxaban is indicated for the prevention of stroke in AF patients.Edoxaban is given orally at a dose of 60 mg once daily.This review reviews advances in the timing and dosage of edoxaban anticoagulant therapy in AF patients after recent ischemic stroke.